Dexcom SHARE receives FDA approval

Dexcom SHARE receives FDA approval

Dexcom has received an FDA approval for its CGM remote mobile communications device, Dexcom SHARE. Said device is an accessory to the Dexcom G4 PLATINUM Continuous Glucose Monitoring System that uses a secure wireless connection to transmit the glucose levels of a person with diabetes to the smartphones of up to five designated recipients, or so called “followers.” These followers can remotely monitor a patient’s glucose information and receive alert notifications from almost anywhere via their iPhone (or iPod touch). For instance, parents and personal caregivers can use Dexcom SHARE to monitor a child’s or loved one’s glucose data from a remote location, giving them peace of mind and reassurance when they are apart.

For instance, parents and personal caregivers can use Dexcom SHARE to monitor a child’s or loved one’s glucose data from a remote location.“With Dexcom SHARE, users, parents and personal caregivers now have a new tool to dramatically improve how they communicate about their diabetes,” said Terrance H. Gregg, CEO of Dexcom.

The Dexcom SHARE consists of a small cradle device in which the Dexcom G4 PLATINUM is docked. The Bluetooth-enabled cradle also functions as a battery charger for the receiver and must be connected to an electrical outlet. The accompanying mobile app uploads glucose data to a secure server, which then enables caregivers or parents to remotely receive notifications about glucose levels and trends on their iOS-based devices.

Diabetes affects 25.8 million Americans and is the 7th leading cause of death in the United States. It is estimated that approximately 79 million Americans over the age of 20 years old are at risk for developing diabetes, largely due to obesity, physical inactivity and poor diet.